← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $170B	2,042	-8	-0.4%	$151B
2	2 Amgen AMGN $239B	1,606	+10	+0.6%	$108B
3	3 Eli Lilly LLY $1.14T	1,229	-18	-1%	$72.7B
4	4 Becton Dickinson BDX $52.5B	1,068	-11	-1%	$40B
5	5 McKesson MCK $116B	877	-32	-4%	$28.5B
6	6 Conagra Brands CAG $6.85B	663	-11	-2%	$11.1B
7	7 Regeneron Pharmaceuticals REGN $83B	606	+2	+0.3%	$32.3B
8	8 Teva Pharmaceutical Industries Limited TEVA $48.2B	537	-113	-17%	$9.5B
9	9 Novo Nordisk NVO $175B	491	+7	+1%	$7.6B
10	10 Lamb Weston LW $7.45B	457	-13	-3%	$5.51B
11	11 AstraZeneca AZN $261B	456	-11	-2%	$12.8B
12	12 DaVita DVA $11.9B	443	-34	-7%	$9.81B
13	13 ResMed RMD $33.9B	363	+23	+7%	$6.84B
14	14 West Pharmaceutical WST $26.9B	302	-8	-3%	$6.72B
15	15 DELISTED CATALENT, INC. CTLT	286	+45	+19%	$5.33B
16	16 Accendra Health ACH $23M	260	-13	-5%	$1.77B
17	17 Opko Health OPK $1.18B	234	+2	+0.9%	$902M
18	18 Fresenius Medical Care FMS $11.8B	205	+16	+8%	$912M
19	19 Herbalife HLF $1.52B	193	-14	-7%	$6.76B
20	20 Medifast MED $137M	168	+7	+4%	$616M
21	21 DELISTED WW International WW	168	+17	+11%	$2.46B
22	22 Tootsie Roll Industries TR $2.93B	162	-10	-6%	$530M
23	23 Lexicon Pharmaceuticals LXRX $725M	137	+1	+0.7%	$1.41B
24	TWNK 24 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	133	-1	-0.7%	$1.4B
25	25 Alaunos Therapeutics TCRT $5.26M	122	0	0%	$356M